Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
(Created page with "== Management == * Ceftolozane-tazobactam ** * Ceftazidime-avibactam ** Special Access Program * Fosfomycin ** * Colistin ** * Cefiderocol ** Special A...") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | ==Management== |
| − | * |
+ | *[[Ceftolozane-tazobactam]] (Zerbaxa) |
| + | |||
| ⚫ | |||
| + | * |
||
| − | * [[Ceftazidime-avibactam]] |
||
| + | |||
| − | ** Special Access Program |
||
| + | *[[Ceftazidime-avibactam]]: available through Special Access Program |
||
| − | * |
+ | *[[Fosfomycin]] |
| ⚫ | |||
| ⚫ | |||
| − | * |
+ | *[[Colistin]] |
| − | ** |
||
| ⚫ | |||
| − | * [[Cefiderocol]] |
||
| − | * |
+ | *[[Cefiderocol]]: available through Special Access Program as well as preapproval by manufacturer |
| − | * |
+ | *[[Meropenem-vaborbactam]]: still awaiting Health Canada Drug Review |
| − | * |
+ | *[[Imipenem-relebactam]] (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review |
| − | * [[Imipenem-relebactam]] |
||
| − | ** Really imipenem-cilastatin-relebactam |
||
| − | ** Awaiting Health Canada Drug Review |
||
Revision as of 09:29, 26 August 2020
Management
- Ceftolozane-tazobactam (Zerbaxa)
- Ceftazidime-avibactam: available through Special Access Program
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
